Literature DB >> 9512334

Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy.

F Landoni1, A Pellegrino, G Cormio, R Milani, A Maggioni, C Mangioni.   

Abstract

AIM: To evaluate the role of platin-based chemotherapy followed by salvage surgery in patients with recurrent ovarian cancer after negative second-look laparotomy.
METHODS: A retrospective chart review was conducted on 38 patients with recurrent ovarian cancer after a pathologic complete response to first-line chemotherapy. After diagnosis of recurrence all patients underwent retreatment with platin-based chemotherapy followed by radical salvage surgery.
RESULTS: Recurrent disease was diagnosed at a median interval of 22 months after second-look surgery. All patients had complete surgical debulking with no macroscopic tumor at the completion of the surgical procedure. Eight patients (21%) required an intestinal resection but no colostomy was performed. Two operative deaths occurred (5%). Twenty-two patients (58%) experienced a second recurrence after salvage surgery The median survival time for all patients after diagnosis of recurrent disease was 29 months (range 6-96 months), with nine patients (25%) surviving more than three years. Survival time after diagnosis of recurrence was not significantly related either to known prognostic factors of ovarian cancer or to the length of the clinical remission time.
CONCLUSION: Retreatment with platin-based chemotherapy followed by salvage surgery should be offered to recurrent ovarian cancer patients and would appear to prolong survival in a highly selected group of patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512334

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  7 in total

1.  Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.

Authors:  Rani Akhil Bhat; Yin Nin Chia; Yong Kuei Lim; Kwai Lam Yam; Cindy Lim; Melissa Teo
Journal:  Oman Med J       Date:  2015-09

Review 2.  Secondary cytoreduction for patients with recurrent ovarian cancer.

Authors:  Teresa P Díaz-Montes; Robert E Bristow
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

3.  Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection.

Authors:  T Onda; H Yoshikawa; T Yasugi; M Yamada; K Matsumoto; Y Taketani
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

4.  Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer.

Authors:  Xia Xu; Xiaoxiang Chen; Zhiqin Dai; Fei Deng; Junwei Qu; Jing Ni
Journal:  J Exp Clin Cancer Res       Date:  2013-09-02

Review 5.  Surgical cytoreduction for recurrent epithelial ovarian cancer.

Authors:  Thuria Al Rawahi; Alberto D Lopes; Robert E Bristow; Andrew Bryant; Ahmed Elattar; Supratik Chattopadhyay; Khadra Galaal
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 6.  Advanced ovarian cancer.

Authors:  M E van der Burg
Journal:  Curr Treat Options Oncol       Date:  2001-04

7.  The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial.

Authors:  Hongyuan Gu; Rui Zhou; Jing Ni; Xia Xu; Xianzhong Cheng; Yan Li; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2020-06-16       Impact factor: 4.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.